Inhibition of poly (ADP-Ribose) polymerase-1 in telomerase deficient mouse embryonic fibroblasts increases arsenite-induced genome instability

Genome Integrity

Volumn 1, Issue , 2010, Pages

  Gurung, Resham L ^a   Balakrishnan, Lakshmidevi ^a   Bhattacharjee, Rabindra N ^b   Manikandan, Jayapal ^a   Swaminathan, Srividya ^a   Hande, M Prakash ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENITE SODIUM; MST 312; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TELOMERASE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL SURVIVAL; CHROMOSOME ABERRATION; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FIBROBLAST; GENE EXPRESSION; GENOMIC INSTABILITY; MICRONUCLEUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

EID: 79953773428     PISSN: None     EISSN: 20419414     Source Type: Journal    
DOI: 10.1186/2041-9414-1-5     Document Type: Article

References (42)

1. Blackburn EH. Structure and function of telomeres. Nature 1991, 350:569-573. 10.1038/350569a0, 1708110.
2. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005, 19:2100-2110. 10.1101/gad.1346005, 16166375.
3. Blackburn EH. Switching and signaling at the telomere. Cell 2001, 106:661-673. 10.1016/S0092-8674(01)00492-5, 11572773.
4. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460. 10.1038/345458a0, 2342578.
5. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965, 37:614-636. 10.1016/0014-4827(65)90211-9, 14315085.
6. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015. 10.1126/science.7605428, 7605428.
7. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995, 269:1236-1241. 10.1126/science.7544491, 7544491.
8. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997, 277:955-959. 10.1126/science.277.5328.955, 9252327.
9. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997, 91:25-34. 10.1016/S0092-8674(01)80006-4, 9335332.
10. Niida H, Matsumoto T, Satoh H, Shiwa M, Tokutake Y, Furuichi Y, et al. Severe growth defect in mouse cells lacking the telomerase RNA component. Nat Genet 1998, 19:203-206. 10.1038/580, 9620783.
11. Hande MP, Samper E, Lansdorp P, Blasco MA. Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice. J Cell Biol 1999, 144:589-601. 10.1083/jcb.144.4.589, 2132934, 10037783.
12. d'adda di Fagnana F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426:194-198. 10.1038/nature02118, 14608368.
13. Espejel S, Klatt P, Menissier-de MJ, Martin-Caballero J, Flores JM, Taccioli G, et al. Impact of telomerase ablation on organismal viability, aging, and tumorigenesis in mice lacking the DNA repair proteins PARP-1, Ku86, or DNA-PKcs. J Cell Biol 2004, 167:627-638. 10.1083/jcb.200407178, 2172587, 15545322.
14. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003, 13:1549-1556. 10.1016/S0960-9822(03)00542-6, 12956959.
15. Jeggo PA. DNA repair: PARP-another guardian angel?. Curr Biol 1998, 8:R49-R51. 10.1016/S0960-9822(98)70032-6, 9427640.
16. Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?. Mutat Res 2000, 460:1-15.
17. Dantzer F, Ame JC, Schreiber V, Nakamura J, Menissier-de MJ, de Murcia G. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair. Methods Enzymol 2006, 409:493-510. 10.1016/S0076-6879(05)09029-4, 16793420.
18. Mortusewicz O, Ame JC, Schreiber V, Leonhardt H. Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells. Nucleic Acids Res 2007, 35:7665-7675. 10.1093/nar/gkm933, 2190722, 17982172.
19. Dantzer F, de La Rubia G, Menissier-de MJ, Hostomsky Z, de Murcia G, Schreiber V. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry 2000, 39:7559-7569. 10.1021/bi0003442, 10858306.
20. Miwa M, Masutani M. PolyADP-ribosylation and cancer. Cancer Sci 2007, 98:1528-1535. 10.1111/j.1349-7006.2007.00567.x, 17645773.
21. Ame JC, Spenlehauer C, de MG. The PARP superfamily. Bioessays 2004, 26:882-893. 10.1002/bies.20085, 15273990.
22. d'adda di Fagnana F, Hande MP, Tong WM, Lansdorp PM, Wang ZQ, Jackson SP. Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability. Nat Genet 1999, 23:76-80.
23. Beneke S, Cohausz O, Malanga M, Boukamp P, Althaus F, Burkle A. Rapid regulation of telomere length is mediated by poly(ADP-ribose) polymerase-1. Nucleic Acids Res 2008, 36:6309-6317. 10.1093/nar/gkn615, 2577345, 18835851.
24. de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997, 94:7303-7307. 10.1073/pnas.94.14.7303, 23816, 9207086.
25. Poonepalli A, Balakrishnan L, Khaw AK, Low GK, Jayapal M, Bhattacharjee RN, et al. Lack of poly(ADP-ribose) polymerase-1 gene product enhances cellular sensitivity to arsenite. Cancer Res 2005, 65:10977-10983. 10.1158/0008-5472.CAN-05-2336, 16322246.
26. Gomez M, Wu J, Schreiber V, Dunlap J, Dantzer F, Wang Y, et al. PARP1 Is a TRF2-associated poly(ADP-ribose)polymerase and protects eroded telomeres. Mol Biol Cell 2006, 17:1686-1696. 10.1091/mbc.E05-07-0672, 1415310, 16436506.
27. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet 2001, 10:677-685. 10.1093/hmg/10.7.677, 11257099.
28. Akiyama M, Hideshima T, Munshi NC, Anderson KC. Telomerase inhibitors as anticancer therapy. Curr Med Chem Anticancer Agents 2002, 2:567-575. 10.2174/1568011023353778, 12678724.
29. Shay JW, Wright WE. Mechanism-based combination telomerase inhibition therapy. Cancer Cell 2005, 7:1-2. 10.1016/j.ccr.2004.12.012, 15652743.
30. Newman JP, Banerjee B, Fang W, Poonepalli A, Balakrishnan L, Low GK, et al. Short dysfunctional telomeres impair the repair of arsenite-induced oxidative damage in mouse cells. J Cell Physiol 2008, 214:796-809. 10.1002/jcp.21276, 17849448.
31. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Soto M, et al. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Recent Pat Anticancer Drug Discov 2006, 1:39-53. 10.2174/157489206775246430, 18221025.
32. Durkacz BW, Shall S, Irwin J. The effect of inhibition of (ADP-ribose)n biosynthesis on DNA repair assayed by the nucleoid technique. Eur J Biochem 1981, 121:65-69. 10.1111/j.1432-1033.1981.tb06430.x, 7327171.
33. Seimiya H, Oh-hara T, Suzuki T, Naasani I, Shimazaki T, Tsuchiya K, et al. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer Ther 2002, 1:657-665.
34. Niida H, Shinkai Y, Hande MP, Matsumoto T, Takehara S, Tachibana M, et al. Telomere maintenance in telomerase-deficient mouse embryonic stem cells: characterization of an amplified telomeric DNA. Mol Cell Biol 2000, 20:4115-4127. 10.1128/MCB.20.11.4115-4127.2000, 85781, 10805753.
35. Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 2005, 7:25-37. 10.1016/j.ccr.2004.11.021, 15652747.
36. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, et al. Mammalian telomeres end in a large duplex loop. Cell 1999, 97:503-514. 10.1016/S0092-8674(00)80760-6, 10338214.
37. Karlseder J. Telomere repeat binding factors: keeping the ends in check. Cancer Lett 2003, 194:189-197. 10.1016/S0304-3835(02)00706-1, 12757977.
38. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917. 10.1038/nature03443, 15829966.
39. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921. 10.1038/nature03445, 15829967.
40. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG01469, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008, 14:7917-7923. 10.1158/1078-0432.CCR-08-1223, 2652879, 19047122.
41. Hande MP, Boei JJ, Natarajan AT. Induction and persistence of cytogenetic damage in mouse splenocytes following whole-body X-irradiation analysed by fluorescence in situ hybridization. II. Micronuclei. Int J Radiat Biol 1996, 70:375-383. 10.1080/095530096144842, 8862448.
42. Hande MP, Boei JJ, Natarajan AT. Induction and persistence of cytogenetic damage in mouse splenocytes following whole-body X-irradiation analysed by fluorescence in situ hybridization. III. Chromosome malsegregation/aneuploidy. Mutagenesis 1997, 12:125-131. 10.1093/mutage/12.3.125, 9175636.